Bliss GVS Pharma Limited has issued a postal ballot notice seeking shareholder approval for the appointment of Santosh Parab as a director. The resolution aims to formalize his role as a non-executive, non-independent director following his initial appointment as an additional director on July 3, 2026.

The company’s Board of Directors approved the appointment based on the recommendation of the Nomination and Remuneration Committee. Mr. Parab, a Chartered Accountant with over 35 years of experience in audit, taxation, and corporate finance, brings expertise from previous roles at State Bank of India, ICICI Bank, and Kotak Mahindra Bank. He currently holds 2,300 equity shares in the company.

Voting Process and Timeline

Shareholders holding shares as of the cut-off date, August 14, 2026, are eligible to vote via the remote e-voting facility provided by Central Depository Services (India) Limited (CDSL). The voting window is strictly defined:

• Start Date: August 21, 2026, at 9:00 am
• End Date: September 19, 2026, at 5:00 pm
• Result Declaration: On or before September 22, 2026

The company will not dispatch physical ballot forms. Notices have been sent electronically to members with registered email addresses through the Registrar and Share Transfer Agent, MUFG Intime India Private Limited.

Governance Details

Mr. Vijay Yadav, Partner at AVS & Associates, has been appointed as the scrutinizer for the postal ballot process. His report on the validity of votes cast will be final. The resolution requires an ordinary majority for passage.

Mr. Parab is not related to any other director or key managerial personnel of the company. He attended one board meeting during the fiscal year 2025-26 prior to this appointment. The board stated that his continued association would strengthen governance and support long-term strategic objectives.

Bliss GVS Pharma Limited ( Bliss GVS Pharma ) reported a significant improvement in profitability for the first quarter of FY27, with consolidated net profit rising 83% year-on-year to ₹513.72 lakh. The Mumbai-based pharmaceutical company posted a consolidated revenue from operations of ₹2,951.75 lakh for the quarter ended June 30, 2026, compared to ₹2,429.23 lakh in the corresponding period of FY26.

The results reflect strong operational momentum across both standalone and consolidated entities. Standalone net profit for the quarter reached ₹386.18 lakh, up from ₹210.53 lakh in Q1FY26, representing an 83% growth. Standalone revenue from operations expanded by 32% to ₹2,303.47 lakh, driven by increased sales volumes and market penetration.

Financial Performance Highlights

Profit before tax for the consolidated entity stood at ₹754.83 lakh, a 20% increase from ₹631.11 lakh in the previous year’s quarter. The standalone profit before tax saw a sharper rise of 67%, reaching ₹512.09 lakh against ₹305.63 lakh in Q1FY26. This divergence suggests improved efficiency or lower tax burdens at the group level relative to the parent company.

What the Numbers Show

The disproportionate growth in net profit compared to revenue highlights margin expansion. While consolidated revenue grew 21%, net profit surged 83%, indicating effective cost management or favorable product mix shifts. Similarly, standalone revenue growth of 32% outpaced the consolidated figure, suggesting the parent entity is capturing higher-value opportunities or benefiting from reduced inter-company eliminations in the current quarter.

Earnings per share (basic) on a consolidated basis rose to ₹4.73 from ₹4.08 in Q1FY26, while standalone basic EPS jumped to ₹3.65 from ₹2.00. The equity share capital remained stable at ₹106.06 lakh, confirming no dilution during the period.

Year-to-Date Context

For the full fiscal year ended March 31, 2026, Bliss GVS Pharma reported consolidated revenue of ₹10,006.43 lakh and a net profit of ₹1,347.28 lakh. The current quarter’s performance contributes positively to the annual trajectory, with Q1FY27 revenue already exceeding 29% of the previous year’s total consolidated income.

The company published these unaudited standalone and consolidated financial results under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were filed with the National Stock Exchange of India Limited and BSE Limited on August 14, 2026.